Penicillin Allergy in China: Consequences of Inappropriate Skin Testing Practices and Policies

Abstract

Penicillins are the most frequently prescribed class of medications worldwide and first‐line antibiotic of choice for most bacterial infections. They are also commonly labelled as the culprit of drug ‘allergy’; leading to obligatory use of second‐line antibiotics, suboptimal antibiotic therapy and increased antimicrobial resistance. However, the majority of reported penicillin ‘allergy’ labels are found to be incorrect after allergy testing, emphasising the importance of proper drug allergy testing and evaluation. Penicillin skin testing (PST) remains an important component of drug allergy diagnosis; however, its practice and policies significantly differ across the world. Inappropriate and non‐evidence‐based PST practices can lead to consequences associated with allergy mislabelling. Even within different regions of China, with a population exceeding 1.4 billion, there are marked differences in the implementation, execution and interpretation of PST. This review aims to examine the differences in PST between Mainland China, Hong Kong and the rest of the world. We critically analyse the current practice of ‘pre‐emptive’ PST in Mainland China, which has a significant false‐positive rate leading to high levels of penicillin allergy mislabelling. Non‐evidence‐based practices further compound the high false‐positive rates of indiscriminatory PST. We postulate that inappropriate PST policies and practices may exacerbate the mislabelling of penicillin allergy, leading to unnecessary overuse of inappropriate second‐line antibiotics, increasing antimicrobial resistance and healthcare costs. We advocate for the importance of more collaborative research to improve the contemporary workflow of penicillin allergy diagnosis, reduce mislabelling and promote the dissemination of evidence‐based methods for allergy diagnosis.